Assembly Biosciences director granted 8,000 stock options

ASSEMBLY BIOSCIENCES, INC. director Gina Consylman received a grant of stock options covering 8,000 shares of common stock.

Rhea-AI Filing Summary

ASSEMBLY BIOSCIENCES, INC. director Gina Consylman received a grant of stock options covering 8,000 shares of common stock. The options have an exercise price of $24.11 per share and represent compensation rather than an open-market purchase.

The options vest, assuming continuous service, on the earlier of June 4, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Consylman holds 8,000 stock options directly, with an expiration date in 2036.

Insider Trade Summary

Grant/Award: 8,000 shares

Grant/Award 1 txn

Insider Consylman Gina

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	8,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 8,000 contracts (Direct)

Footnotes (1)

1. F1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Options granted: 8,000 options Exercise price: $24.11 per share Underlying shares: 8,000 shares +2 more

5 metrics

Options granted 8,000 options Stock option grant to director Gina Consylman

Exercise price $24.11 per share Strike price for the 8,000 stock options

Underlying shares 8,000 shares Common stock underlying the options

Expiration date 2036-06-04 Option expiration for this grant

Vesting date trigger June 4, 2027 Latest vesting date, subject to earlier 2027 annual meeting

Key Terms

stock options, exercise price, continuous service, annual meeting of stockholders, +1 more

5 terms

stock options financial

"Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027..."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price": "24.1100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027..."

annual meeting of stockholders financial

"upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders."

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Gina Consylman report in the ASMB Form 4 filing?

Gina Consylman reported receiving stock options for 8,000 shares of Assembly Biosciences common stock. These options are a compensation grant, not an open-market trade, and give her the right to buy shares at a fixed exercise price.

What is the exercise price of the new ASMB stock options?

The new stock options granted to Gina Consylman have an exercise price of $24.11 per share. This means she can buy Assembly Biosciences common stock at this price once the options vest and remain exercisable until their expiration date.

When do Gina Consylman’s ASMB stock options vest?

The 8,000 Assembly Biosciences stock options vest upon the earlier of June 4, 2027 or the company’s 2027 annual meeting. Vesting requires her to maintain continuous service with the company through that vesting date, according to the disclosure footnote.

How many ASMB options does Gina Consylman hold after this grant?

After this grant, Gina Consylman directly holds stock options for 8,000 shares of Assembly Biosciences common stock. The Form 4 shows this as her total option position following the transaction, reflecting a single compensation award reported in this filing.

Is Gina Consylman’s ASMB Form 4 transaction a stock purchase or sale?

The Form 4 reflects a grant of stock options, not a purchase or sale of common shares. It is recorded under a grant or award code, meaning she received derivative securities as compensation with future rights to acquire common stock at a set price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:35 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Consylman Gina

(Last) (First) (Middle)

C/O ASSEMBLY BIOSCIENCES, INC.

TWO TOWER PLACE, 7TH FLOOR

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASSEMBLY BIOSCIENCES, INC. [ ASMB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$24.11	06/04/2026		A		8,000		(1)	06/04/2036	Common Stock	8,000	$0	8,000	D

Explanation of Responses:

1. Grant of stock options. The stock options vest, assuming continuous service, upon the earlier of (1) June 4, 2027 and (2) the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ John O. Gunderson, as Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)